Princeton, NJ, November 10, 2017 --(PR.com
)-- The Chinese drug market growth is expected to fall further to 7.6% valued at CNY 1,611.8 billion (at retail price level) in 2017 as a result of tender price pressure, eliminated hospital drug sales margin and stringent government cost containment measures, according to WiCON|Pharma China (www.pharmachinaonline.com) quoting Jianning Lin, President of the Southern Medicine Economic Institute (SMEI) under the CFDA who delivered a keynote presentation, Medicine Economic Outlook in 2018 and the Next Five Years, at the at the 29th National Medicine Economic Information Release Conference.
The sales of the Chinese pharmaceutical industry were up 12.3% to CNY 2,347.5 billion in the first nine months of 2017, official data quoted by WiCON|Pharma China (www.pharmachinaonline.com) shows. The same full year 2017 figure is expected to be 13.0% and CNY 3,329.3 billion. The output value growth rate also set a record high in 2011 at 26.1% and began to fall thereafter. But it started to rebound somewhat from 2016.
Lin believes that expected Chinese macro-economic policies in 2018 will be advantageous for the pharmaceutical industry with possibly higher government healthcare investments. However, he has concerns over the country’s monetary policies and offline economy.
As the government’s healthcare policies including the two-invoice measure get implemented, Lin predicts changes to the business model of pharmaceutical industry in China, more consolidation of the Chinese pharmaceutical distribution sector, faster growth of the pharmaceutical manufacturing sector and falling growth of distributor sales.
WiCON|Pharma China (www.pharmachinaonline.com) reported forecasts by SMEI of 7% growth for the Chinese hospital drug market in 2017 with a value of CNY 1,975.5 billion. SMEI predicts continued falling growth of retail pharmacy and primary healthcare facility drug sales. The drug sales of retail pharmacy and primary healthcare facility sectors is projected to grow 8% and 11.6% respectively to CNY 364.7 billion and CNY 151.7 billion in 2017.
SMEI also anticipates more stringent cost containment by the government in 2018 in aspects including global budget control, structural drug rationalization, BMI payment price reform, capping of drug sales share in healthcare expenditures, and control of supplementary and large consumption volume drugs.
WiCON|Pharma China (www.pharmachinaonline.com) is the most trusted English media and business intelligence service covering the Chinese pharmaceutical / biopharmaceutical marketplace. It caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies.
Please join the 2017 Winter Promotion for Pharma China products. The following compliments will be offered to new subscribers of any Pharma China products or packages who order before December 31, 2017: 1) full English translation of the amendment draft of Provisions for Registration of Drug Products, and 2) six complimentary back issues of Pharma China Journal Edition in PDF.
Fresh with newly updated data and contents, the new edition of China Pharmaceutical Guide (2017 or 12th Edition) was officially published on August 31. Besides, China Pharmaceutical Guide 2016 (11th Edition) is now on sale at 50% discount.
Pharma China is the most-trusted English media and intelligence service covering China's pharmaceutical sector, and it is subscribed by all multinational pharmaceutical companies operating in China, leading CROs and service providers, consulting firms, investment banks, industry associations and government agencies.
Act now and make informed decisions and stay in the driver seat of China business.
The followings are a list of WiCON|Pharma China's products and value package. All customers receive the premium edition of weekly e-alerts and breaking news e-alerts.
1. Pharma China Journal Edition: monthly journal in Print or PDF (US$1,800 or CNY 13,000)
2. Pharma China Web Edition: Unlimited 24-hour access to premium news and features articles on our website (US$2,400 or CNY 17,500)
3. Pharma China Gold Pakcage: includes Journal Edition, Web Edition, Archives and Online Databases (US$2,950 or CNY 21,500)
4. China Pharmaceutical Guide 2017 (12th Edition): PDF (US$4,100 or CNY 30,000), Print (US$4,200 or CNY 30,500).
5. China Pharmaceutical Guide 2017 (buy individual volumes): Volume I – Overview of the Chinese Pharmaceutical & Healthcare Sectors, Volume II – Chinese Pharmaceutical IP and Regulatory Guide; Volume III – Annual Review, Trends, Opportunities and Strategic Considerations; and Volume IV – Sales & Marketing, Entry Strategies and Case Studies. Buy 1 or 2 individual volumes at $2,500 or $3,200.
5. China Pharmaceutical Guide 2016 (11th Edition): on sale at 50% discount at US$2,100 or CNY 15,500
6. Pharma China Platinum Package: includes the gold package and China Pharmaceutical Guide 2016 or 2017 (US$5,800 or CNY 42,000)
To order or receive more information on WiCON|Pharma China's products and services, please email James Shen (firstname.lastname@example.org) or fax (+1 801-7515728).